Spectral Medical Company Description
Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally.
The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream.
It also develops, manufactures, and markets monoclonal and polyclonal antibodies, recombinant cardiac proteins, antibodies, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies.
The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014.
Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.
| Country | Canada |
| Founded | 1991 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Christopher Seto |
Contact Details
Address: 135 The West Mall Toronto, Ontario M9C 1C2 Canada | |
| Phone | 416 626 3233 |
| Website | spectraldx.com |
Stock Details
| Ticker Symbol | EDTXF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| ISIN Number | CA8475771033 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Christopher Seto | Chief Executive Officer, Chief Financial Officer and Director |
| Dr. John A. Kellum M.D. | Chief Medical Officer |